The Na+/I- Symporter (NIS): Mechanism and medical impact

Endocrine Reviews

Volumn 35, Issue 1, 2014, Pages 106-149

  Portulano, Carla ^a,c   Paroder Belenitsky, Monika ^b,d   Carrasco, Nancy ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^d Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; IODOTYROSINE; LITHIUM ION; POTASSIUM CHANNEL KCNQ1; PROLACTIN; SEROTONIN TRANSPORTER; SODIUM IODIDE SYMPORTER; SODIUM ION; THYROID HORMONE; THYROTROPIN; TRACE ELEMENT;

AMINO ACID SUBSTITUTION; ARTICLE; BREAST; BREAST CANCER; CANCER THERAPY; CEPHALOCHORDATA; CHORDATA; COGNITION; COGNITIVE DEFECT; CONFORMATIONAL TRANSITION; CONGENITAL HYPOTHYROIDISM; DIETARY INTAKE; EMBRYONAL TISSUE; ENDEMIC GOITER; ENZYME SPECIFICITY; FETUS (ANATOMY); FETUS DEVELOPMENT; GENE TRANSFER; GOITER; HORMONE SYNTHESIS; HOST RESISTANCE; HUMAN; HUMAN DEVELOPMENT; HYPERTHYROIDISM; HYPOPHYSIS; HYPOTHYROIDISM; INVERTEBRATE; IODINE DEFICIENCY; KIDNEY; LYTECHINUS; LYTECHINUS VARIEGATUS; MUTATION; NEGATIVE FEEDBACK; NONHUMAN; PLACENTA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REGULATORY MECHANISM; REPORTER GENE; SALIVARY GLAND; SIGNAL TRANSDUCTION; SMALL INTESTINE; SPONTANEOUS ABORTION; STILLBIRTH; STOICHIOMETRY; STOMACH; THYROID CANCER; THYROID FUNCTION; THYROID GLAND; UROCHORDATA;

HUMANS; IODINE; SYMPORTERS; THYROID GLAND; THYROID HORMONES; THYROID NEOPLASMS;

EID: 84893566627     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1036     Document Type: Article

References (342)

1. Baumann E. Uber den Jodgehalt der Schilddrusen von Menchen und tieren. HoppeSeylersZPhysiolChem. 1986; 22:1-17.
2. Baumann E. Uber das Thyrojodin. Munch Med Wschr. 1896;43:309-312.
3. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning of metastases of adenocarcinomas of the thyroid. J Am Med Assoc. 1946;132:838-847.
4. Dai G, Levy O, Amzel LM, Carrasco N.The mediator of thyroidal iodide accumulation: the sodium/iodide symporter. In: Konings WN, Kaback HR, Lolkema JS, eds. Handbook of Biological Physics; Vol. II, Transport Processes in Eukaryotic and Prokaryotic Organisms. Amsterdam, The Netherlands: Elsevier Science BV; 1996;343-367.
5. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458-460.
6. Vescia FG, Basso L. Goiters in the Renaissance. Vesalius. 1997;3:23-32.
7. Delange F, Bürgi H, Chen ZP, Dunn JT. World status of monitoring iodine deficiency disorders control programs. Thyroid. 2002;12:915-924.
8. Pharoah PO, Buttfield IH, Hetzel BS. Neurological damage to the fetus resulting from severe iodine deficiency during pregnancy. Lancet. 1971;1:308-310.
9. Dunn JT, Delange F. Damaged reproduction: the most important consequence of iodine deficiency. J Clin Endocrinol Metab. 2001;86:2360-2363.
10. Morreale de Escobar G, Obregón MJ, Escobar del Rey F. Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? J Clin Endocrinol Metab. 2000;85:3975-3987.
11. Bleichrodt N, Born MP. A meta-analysis of research on iodine and its relationship to cognitive development. In: Stanbury JB, ed. The Damaged Brain of Iodine Deficiency. New York, NY: Cognizant Communication; 1994;195-200.
12. Vitti P RT, Aghini-Lombardi F, Chiovato L, Ferretti G, Pinchera A. Neuropsychological assessment in humans living in mild to moderate iodine deficiency. In: Morreale de Escobar G, de Vijlder JJM, Butz S, Hostalek U, eds. The Thyroid and Brain. Merck European Thyroid Symposium, Seville 2002. May 30-June 2. Stuttgart, Germany Schattauer; 2003:57-63.
13. Santiago-Fernandez P, Torres-Barahona R, Muela- Martínez JA, et al. Intelligence quotient and iodine intake: a cross-sectional study in children. J Clin Endocrinol Metab. 2004;89:3851-3857.
14. Caldwell KL, Makhmudov A, Ely E, Jones RL, Wang RY. Iodine status of the U.S. population, National Health and Nutrition Examination Survey, 2005-2006 and 2007-2008. Thyroid. 2011;21:419-427.
15. Glinoer D. Iodine nutrition requirements during pregnancy. Thyroid. 2006;16:947-948.
16. de Benoist B, McLean E, Andersson M, Rogers L. Iodine deficiency in 2007: global progress since 2003. Food Nutr Bull. 2008;29:195-202.
17. Li M, Eastman CJ. The changing epidemiology of iodine deficiency. Nat Rev Endocrinol. 2012;8:434-440.
18. Towery BT. The physiology of iodine. Bull World Health Organ. 1953;9:175-182.
19. Mazzaferri EL. 2000 Thyroid diseases: tumors. Radioiodine and other treatment and outcomes. In: Braverman LE, Utiger, R.D. ed. Werner, Ingbar's The Thyroid. 8th ed. Lipincott Williams, Wilkins; 2000:904-930.
20. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 2000;6:469-476.
21. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta. 1993;1154:65-82.
22. Vilkki P. An iodide-complexing phospholipid. Arch Biochem Biophys. 1962;97:425-427.
23. Schneider PB, Wolff J. Thyroidal iodide transport. VI. On a possible role for iodide-binding phospholipids. Biochim Biophys Acta. 1965;94:114-123.
24. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev. 2000;80: 1083-1105.
25. - symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol. 2003;213:59-70.
26. Bernal J. Thyroid hormones and brain development. Vitam Horm. 2005;71:95-122.
27. Saber-Lichtenberg Y, Brix K, Schmitz A, et al. Covalent cross-linking of secreted bovine thyroglobulin by transglutaminase. FASEB J. 2000;14:1005-1014.
28. Bizhanova A, Kopp P. Genetics and phenomics of Pendred syndrome. Mol Cell Endocrinol. 2010;322:83-90.
29. Everett LA, Glaser B, Beck JC, et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet. 1997;17:411-422.
30. Everett LA, Belyantseva IA, Noben-Trauth K, et al. Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome. Hum Mol Genet. 2001;10:153-161.
31. -mice fed on a low iodine diet. J Endocrinol Invest. 2011;34:593-598.
32. - pigs suggests mechanisms for hypothyroidism in cystic fibrosis. Exp Physiol. 2010;95: 1132-1144.
33. De Luca F, Trimarchi F, Sferlazzas C, et al. Thyroid function in children with cystic fibrosis. Eur J Pediatr. 1982; 138:327-330.
34. Segall-Blank M, Vagenakis AG, Shwachman H, Ingbar SH, Braverman LE. Thyroid gland function and pituitary TSHreserve in patients with cystic fibrosis. J Pediatr. 1981; 98:218-222.
35. Steinmeyer K, Schwappach B, Bens M, Vandewalle A, Jentsch TJ. Cloning and functional expression of rat CLC-5, a chloride channel related to kidney disease. J Biol Chem. 1995;270:31172-31177.
36. van den Hove MF, Croizet-Berger K, Jouret F, et al. The loss of the chloride channel, ClC-5, delays apical iodide efflux and induces a euthyroid goiter in the mouse thyroid gland. Endocrinology. 2006;147:1287-1296.
37. Rodriguez AM, Perron B, Lacroix L, et al. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab. 2002;87:3500-3503.
38. +-monocarboxylate cotransporter. J Physiol. 2004;557:719-731.
39. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A. 2003;100:8412-8417.
40. +/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A. 2006;103:7270-7275.
41. Frank H, Gröger N, Diener M, Becker C, Braun T, Boettger T. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. J Biol Chem. 2008;283:24729-24737.
42. Gavaret JM, Cahnmann HJ, Nunez J. Thyroid hormone synthesis in thyroglobulin. The mechanism of the coupling reaction. J Biol Chem. 1981;256:9167-9173.
43. Braverman LE, Utiger RD. Thyroid hormone synthesis. In: Werner and Ingbar's The Thyroid. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004:309-328.
44. Bedard K, Lardy B, Krause KH. NOX family NADPH oxidases: not just in mammals. Biochimie. 2007;89:1107-1112.
45. Donkó A, Péterfi Z, Sum A, Leto T, Geiszt M. Dual oxidases. Philos Trans R Soc Lond B Biol Sci. 2005;360: 2301-2308.
46. Ris-Stalpers C. Physiology and pathophysiology of the DUOXes. Antioxid Redox Signal. 2006;8:1563-1572.
47. Dupuy C, Pomerance M, Ohayon R, et al. Thyroid oxidase (THOX2) gene expression in the rat thyroid cell line FRTL-5. Biochem Biophys Res Commun. 2000;277:287-292.
48. Morand S, Dos Santos OF, Ohayon R, et al. Identification of a truncated dual oxidase 2 (DUOX2) messenger ribonucleic acid (mRNA) in two rat thyroid cell lines. Insulin and forskolin regulation of DUOX2 mRNA levels in FRTL-5 cells and porcine thyrocytes. Endocrinology. 2003;144:567-574.
49. 2 measurement in mouse thyroid: onset in embryonic development and regulation by TSH in adult. J Endocrinol. 2007;192:615-626.
50. Moreno JC, Bikker H, Kempers MJ, et al. Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med. 2002;347:95-102.
51. Zamproni I, Grasberger H, Cortinovis F, et al. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J Clin Endocrinol Metab. 2008;93:605-610.
52. Moreno JC, Visser TJ. Genetics and phenomics of hypothyroidism and goiter due to iodotyrosine deiodinase (DEHAL1) gene mutations. Mol Cell Endocrinol. 2010; 322:91-98.
53. Hoste C, Rigutto S, Van Vliet G, Miot F, De Deken X. Compound heterozygosity for a novel hemizygous missense mutation and a partial deletion affecting the catalytic core of the H2O2-generating enzyme DUOX2 associated with transient congenital hypothyroidism. Hum Mutat. 2010;31:E1304-E1319.
54. Stanbury JB, Litvak J. The metabolism of iodotyrosines. IV. Metabolism of L-diiodotyrosine in patients with hypothyroidism. J Clin Endocrinol Metab. 1957;17:654-657.
55. Stanbury JB, Morris ML. Deiodination of diiodotyrosine by cell-free systems. J Biol Chem. 1958;233:106-108.
56. Rosenberg IN, Goswami A. Purification and characterization of a flavoprotein from bovine thyroid with iodotyrosine deiodinase activity. J Biol Chem. 1979;254:12318-12325.
57. Moreno JC, van Toor H, Pinto G, et al. Mutations in the iodotyrosine deiodinase gene and hypothyroidism.NEngl J Med. 2008;358:1811-1818.
58. DeGroot LJ. Kinetic analysis of iodine metabolism. J Clin Endocrinol Metab. 1966;26:149-173.
59. Stanbury JB, Kassenaar AA, Meijer JW, Terpstra J. The occurrence of mono- and di-iodotyrosine in the blood of a patient with congenital goiter. J Clin Endocrinol Metab. 1955;15:1216-1227.
60. Paris M, Hillenweck A, Bertrand S. Active metabolism of thyroid hormone during metamorphosis of amphioxus. Integr Comp Biol. 2010;50:63-74.
61. ParisM,Brunet F,MarkovGV,SchubertM,Laudet V. The amphioxus genome enlightens the evolution of the thyroid hormone signaling pathway. Dev Genes Evol. 2008;218: 667-680.
62. Eales JG. Iodine metabolism and thyroid-related functions in organisms lacking thyroid follicles: are thyroid hormones also vitamins? Proc Soc Exp Biol Med. 1997;214: 302-317.
63. Saito M, Seki M, Amemiya S, Yamasu K, Suyemitsu T, Ishihara K. Induction of metamorphosis in the sand dollar Peronella japonica by thyroid hormones. Dev Growth Differ. 1998;40:307-312.
64. Heyland A, Reitzel AM, Price DA, Moroz LL. Endogenous thyroid hormone synthesis in facultative planktotrophic larvae of the sand dollar Clypeaster rosaceus: implications for the evolutionary loss of larval feeding. Evol Dev. 2006; 8:568-579.
65. Heyland A, Reitzel AM, Hodin J. Thyroid hormones determine developmental mode in sand dollars (Echinodermata: Echinoidea). Evol Dev. 2004;6:382-392.
66. Miller AE, Heyland A. Endocrine interactions between plants and animals: implications of exogenous hormone sources for the evolution of hormone signaling. Gen Comp Endocrinol. 2010;166:455-461.
67. Heyland A, Moroz LL. Cross-kingdom hormonal signaling: an insight from thyroid hormone functions in marine larvae. J Exp Biol. 2005;208:4355-4361.
68. Chino Y, Saito M, Yamasu K, Suyemitsu T, Ishihara K. Formation of the adult rudiment of sea urchins is influenced by thyroid hormones. Dev Biol. 1994;161:1-11.
69. Küpper FC, Carpenter LJ, McFiggans GB, et al. Iodide accumulation provides kelp with an inorganic antioxidant impacting atmospheric chemistry. Proc Natl Acad Sci U S A. 2008;105:6954-6958.
70. Dehal P, Satou Y, Campbell RK, et al. The draft genome of Ciona intestinalis: insights into chordate and vertebrate origins. Science. 2002;298:2157-2167.
71. - symporter (NIS). Proc Natl Acad Sci U S A. 2011;108: 17933-17938.
72. Fischer AJ, Lennemann NJ, Krishnamurthy S, et al. Enhancement of respiratory mucosal anti-viral defenses by iodide oxidation. Am J Respir Cell Mol Biol. 2011;45: 874-881.
73. Park SM, Chatterjee VK. Genetics of congenital hypothyroidism. J Med Genet. 2005;42:379-389.
74. Szinnai G, Lacroix L, Carré A, et al. Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus. J Clin Endocrinol Metab. 2007;92:70-76.
75. Portella AC, Carvalho F, Faustino L, Wondisford FE, Ortiga- Carvalho TM, Gomes FC. Thyroid hormone receptor β mutation causes severe impairment of cerebellar development. Mol Cell Neurosci. 2010;44:68-77.
76. Morte B, Ceballos A, Diez D, et al. Thyroid hormoneregulated mouse cerebral cortex genes are differentially dependent on the source of the hormone: a study in monocarboxylate transporter-8- and deiodinase-2-deficient mice. Endocrinology. 2010;151:2381-2387.
77. Morte B, Díez D, Ausó E, et al. Thyroid hormone regulation of gene expression in the developing rat fetal cerebral cortex: prominent role of theCa2+/calmodulin-dependent protein kinase IV pathway. Endocrinology. 2010;151: 810-820.
78. Westerholz S, de Lima AD, Voigt T. Regulation of early spontaneous network activity and GABAergic neurons development by thyroid hormone. Neuroscience. 2010;168: 573-589.
79. Tan XJ, Fan XT, Kim HJ, et al. Liver X receptor β and thyroid hormone receptor α in brain cortical layering. Proc Natl Acad Sci U S A. 2010;107:12305-12310.
80. Horn S, Heuer H. Thyroid hormone action during brain development: more questions than answers. Mol Cell Endocrinol. 2010;315:19-26.
81. Melse-Boonstra A, Jaiswal N. Iodine deficiency in pregnancy, infancy and childhood and its consequences for brain development. Best Pract Res Clin Endocrinol Metab. 2010;24:29-38.
82. de Escobar GM, Ares S, Berbel P, Obregón MJ, del Rey FE. The changing role of maternal thyroid hormone in fetal brain development. Semin Perinatol. 2008;32:380-386.
83. Opazo MC, Gianini A, Pancetti F, et al. Maternal hypothyroxinemia impairs spatial learning and synaptic nature and function in the offspring. Endocrinology. 2008;149: 5097-5106.
84. Vulsma T, GonsMH,de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med. 1989;321:13-16.
85. Mitchell ML, Klein RZ. The sequelae of untreated maternal hypothyroidism. Eur J Endocrinol. 2004;151(Suppl 3): U45-U48.
86. Arturi F, Presta I, Scarpelli D, et al. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression. Eur J Endocrinol. 2002;147:655-661.
87. Hershman JM, Lee HY, Sugawara M, et al. Human chorionic gonadotropin stimulates iodide uptake, adenylate cyclase, and deoxyribonucleic acid synthesis in cultured rat thyroid cells. J Clin Endocrinol Metab. 1988;67:74-79.
88. Davies TF, Platzer M. hCG-induced TSH receptor activation and growth acceleration in FRTL-5 thyroid cells. Endocrinology. 1986;118:2149-2151.
89. World Health Organization. Technical consultation for the prevention and control of iodine deficiency in pregnant and lactating women and in children less than two years old. Geneva, Switzerland: World Health Organization; 2007.
90. Berbel P, Obregón MJ, Bernal J, Escobar del Rey F, Morreale de Escobar G. Iodine supplementation during pregnancy: a public health challenge. Trends Endocrinol Metab. 2007;18:338-343.
91. Stanbury J. The Damaged Brain of Iodine Deficiency. Cognitive, Behavioral, Neuromotor, Educative Aspects. New York, NY: Cognizant Communication; 1994.
92. de Escobar GM, Obregón MJ, del Rey FE. Maternal thyroid hormones early in pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab. 2004;18: 225-248.
93. GoodwinTM,MontoroM,Mestman JH, Pekary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab. 1992;75:1333-1337.
94. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997;18:404-433.
95. Hetzel BS. Iodine and neuropsychological development. J Nutr. 2000;130:493S-495S.
96. Calvo RM, Jauniaux E, Gulbis B, et al. Fetal tissues are exposed to biologically relevant free thyroxine concentrations during early phases of development. J Clin Endocrinol Metab. 2002;87:1768-1777.
97. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol. 2004;151(Suppl 3):U25-U37.
98. Glinoer D, Delange F. The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny. Thyroid. 2000;10:871-887.
99. Utiger RD. Maternal hypothyroidism and fetal development. N Engl J Med. 1999;341:601-602.
100. Smit BJ, Kok JH, Vulsma T, Briët JM, Boer K, Wiersinga WM. Neurologic development of the newborn and young child in relation to maternal thyroid function. Acta Paediatr. 2000;89:291-295.
101. Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf). 1999;50:149-155.
102. Pop VJ, Brouwers EP, Vader HL, de Vijlder J, Vulsma T. 2000 Maternal thyroid function during early pregnancy and neurodevelopment of the offspring. Proceedings from the 82nd Annual Meeting of The Endocrine Society, Toronto, Canada, 2000;163.
103. Vagenakis AG, Koutras DA, Burger A, Malamos B, Ingbar SH, Braverman LE. STudies of serum triiodothyronine, thyroxine and thyrotropin concentrations in endemic goiter in Greece. J Clin Endocrinol Metab. 1973;37:485-488.
104. Patel YC, Pharoah PO, Hornabrook RW, Hetzel BS. Serum triiodothyronine, thyroxine and thyroid-stimulating hormone in endemic goiter: a comparison of goitrous and nongoitrous subjects in New Guinea. J Clin Endocrinol Metab. 1973;37:783-789.
105. Pharaoh PO, Lawton NF, Ellis SM, Williams ES, Ekins RP. The role of triiodothyronine (T3) in the maintenance of euthyroidism in endemic goitre. Clin Endocrinol (Oxf). 1973;2:193-199.
106. Abrams GM, Larsen PR. Triiodothyronine and thyroxine in the serum and thyroid glands of iodine-deficient rats. J Clin Invest. 1973;52:2522-2531.
107. Riesco G, Taurog A, Larsen PR. Variations in the response of the thyroid gland of the rat to different low-iodine diets: correlation with iodine content of diet. Endocrinology. 1976;99:270-280.
108. Santisteban P, Obregon MJ, Rodriguez-Peña A, Lamas L, Del Rey FE, De Escobar GM. Are iodine-deficient rats euthyroid? Endocrinology. 1982;110:1780-1789.
109. Chapman A. The relation of the thyroid and the pituitary glands to iodine metabolism. Endocrinology. 1941;29: 680-681.
110. Halmi NS, Spirtos BN. Analysis of the modifying effect of dietary iodine levels on the thyroidal response of hypophysectomized rats to thyrotrophin. Endocrinology. 1955; 56:157-160.
111. Pedraza PE, Obregon MJ, Escobar-Morreale HF, del Rey FE, de Escobar GM. Mechanisms of adaptation to iodine deficiency in rats: thyroid status is tissue specific. Its relevance for man. Endocrinology. 2006;147:2098-2108.
112. - symporter. Mechanism, stoichiometry, and specificity. J Biol Chem. 1997;272: 27230-27238.
113. - symporter with an anti-COOH terminus antibody. Proc Natl Acad SciUS A. 1997;94:5568-5573.
114. - symporter (NIS). Implications for its secondary structure model. J Biol Chem. 1998;273:22657-22663.
115. Dohan O, De la Vieja A, Carrasco N. Molecular study of the sodium-iodide symporter (NIS): a new field in thyroidology. Trends Endocrinol Metab. 2000;11:99-105.
116. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871-878.
117. - symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001; 86:2697-2700.
118. Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem. 2001;276:21458-21463.
119. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984;114:1090-1098.
120. Rhoden KJ, Cianchetta S, Duchi S, Romeo G. Fluorescence quantitation of thyrocyte iodide accumulation with the yellow fluorescent protein variant YFP-H148Q/I152L. Anal Biochem. 2008;373:239-246.
121. --transporting cultured thyroid cells. Proc Natl Acad Sci U S A. 1994;91:3789-3793.
122. Dohán O, De la Vieja A, Paroder V, et al. The sodium/ iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48-77.
123. - symporter (NIS) is regulated by its carboxy terminus. In: European Congress of Endocrinology 2007. Budapest, Hungary: BioScientifica; 2007.
124. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun. 1996;226:339-345.
125. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004;447:510-518.
126. Van Sande J, Massart C, Beauwens R, et al. Anion selectivity by the sodium iodide symporter. Endocrinology. 2003;144:247-252.
127. Wolff J. Transport of iodide and other anions in the thyroid gland. Physiol Rev. 1964;44:45-90.
128. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med. 2004;45:500-507.
129. +/I symporter (NIS) mediates electroneutral active transport of the environmental pollutant perchlorate. Proc Natl Acad Sci U S A. 2007;104: 20250-20255.
130. +/glucose cotransporter (SGLT1). J Biol Chem. 1994;269:21407-21410.
131. + permeation and pH regulation at a mammalian serotonin transporter. J Neurosci. 1997;17:2257-2266.
132. +-dependent I- transport system in plasma membrane vesicles from thyroid glands. Biochim Biophys Acta. 1987; 896:263-274.
133. + dependence and are critical for transport activity. J Biol Chem. 2007;282:25290-25298.
134. --dependent neurotransmitter transporters. Nature. 2005;437: 215-223.
135. +/sugar symport. Science. 2008; 321:810-814.
136. Weyand S, Shimamura T, Yajima S, et al. Structure and molecular mechanism of a nucleobase-cation-symport-1 family transporter. Science. 2008;322:709-713.
137. Fang Y, Jayaram H, Shane T, et al. Structure of a prokaryotic virtual protonpumpat 3.2Aresolution. Nature. 2009; 460:1040-1043.
138. Gao X, Lu F, Zhou L, et al. Structure and mechanism of an amino acid antiporter. Science. 2009;324:1565-1568.
139. +-independent amino acid transporter. Science. 2009;325:1010-1014.
140. Godley AF, Stanbury JB. Preliminary experience in the treatment of hyperthyroidism with potassium perchlorate. J Clin Endocrinol Metab. 1954;14:70-78.
141. Crooks J, Wayne EJ. A comparison of potassium perchlorate, methylthiouracil, and carbimazole in the treatment of thyrotoxicosis. Lancet. 1960;1:401-404.
142. Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab. 1984;58:62-69.
143. Reichert LJ, de Rooy HA. Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. BMJ. 1989; 298:1547-1548.
144. Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest. 1986;9:201-207.
145. Yoshida A, Sasaki N, Mori A, et al. Differences in the electrophysiological response to I- and the inhibitory anions SCN- and ClO-4, studied in FRTL-5 cells. Biochim Biophys Acta. 1998;1414:231-237.
146. Goldman SJ, Stanbury JB. The metabolism of perchlorate in the rat. Endocrinology. 1973;92:1536-1538.
147. Chow SY, Woodbury DM. Kinetics of distribution of radioactive perchlorate in rat and guinea-pig thyroid glands. J Endocrinol. 1970;47:207-218.
148. - symporter. Biochem Biophys Res Commun. 1997;231:731-734.
149. Cianchetta S, di Bernardo J, Romeo G, Rhoden KJ. Perchlorate transport and inhibition of the sodium iodide symporter measured with the yellow fluorescent protein variant YFP-H148Q/I152L. Toxicol Appl Pharmacol. 2010; 243:372-380.
150. Valentín-Blasini L, Mauldin JP, Maple D, Blount BC. Analysis of perchlorate in human urine using ion chromatography and electrospray tandem mass spectrometry. Anal Chem. 2005;77:2475-2481.
151. Capuco AV, Rice CP, Baldwin RL 6th, et al. Fate of dietary perchlorate in lactating dairy cows: Relevance to animal health and levels in the milk supply. Proc Natl Acad Sci U S A. 2005;102:16152-16157.
152. Kirk AB, Martinelango PK, Tian K, Dutta A, Smith EE, Dasgupta PK. Perchlorate and iodide in dairy and breast milk. Environ Sci Technol. 2005;39:2011-2017.
153. Tran N, Valentín-Blasini L, Blount BC, et al. Thyroidstimulating hormone increases active transport of perchlorate into thyroid cells. Am J Physiol Endocrinol Metab. 2008;294:E802-E806.
154. American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 2006; 117:2290-2303.
155. Clifton-Bligh RJ, Wentworth JM, Heinz P, et al. Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. Nat Genet. 1998; 19:399-401.
156. Pohlenz J, Dumitrescu A, Zundel D, et al. Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. J Clin Invest. 2002;109:469-473.
157. Macchia PE, Lapi P, Krude H, et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet. 1998;19:83-86.
158. Krude H, Schütz B, Biebermann H, et al. Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest. 2002;109:475-480.
159. Dentice M, Cordeddu V, Rosica A, et al. Missense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesis. J Clin Endocrinol Metab. 2006;91:1428-1433.
160. Pohlenz J, Refetoff S. Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Biochimie. 1999;81:469-476.
161. Gutnisky VJ, Moya CM, Rivolta CM, et al. Two distinct compound heterozygous constellations (R277X/IVS34-1G>C and R277X/R1511X) in the thyroglobulin (TG) gene in affected individuals of a Brazilian kindred with congenital goiter and defective TG synthesis. J Clin Endocrinol Metab. 2004;89:646-657.
162. Avbelj M, Tahirovic H, Debeljak M, et al. High prevalence of thyroid peroxidase gene mutations in patients with thyroid dyshormonogenesis. Eur J Endocrinol. 2007;156: 511-519.
163. - symporter (NIS) mutant that causes congenital I- transport defect (ITD). Endocrinology. 2008;149(6):3077-3084.
164. - symporter activity requires a small and uncharged amino acid residue at position 395. Mol Endocrinol. 2002;16:1893-1902.
165. - symporter (NIS). J Cell Sci. 2013; 126(Pt 15):3305-3313.
166. De La Vieja A, Ginter CS, Carrasco N. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number. J Cell Sci. 2004;117:677-687.
167. Montanelli L, Agretti P, Marco G, et al. Congenital hypothyroidism and late-onset goiter: identification and characterization of a novel mutation in the sodium/iodide symporter of the proband and family members. Thyroid. 2009; 19:1419-1425.
168. - symporter (NIS). FASEB J. 2013;27:3229-3238.
169. - symporter. Mol Endocrinol. 2005;19:2847-2858.
170. - symporter 5'-untranslated region in a patient with congenital hypothyroidism. J Clin Endocrinol Metab. 2011;96:E1100-E1107.
171. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem. 1996;271:635-638.
172. Tamarappoo BK, Verkman AS. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest. 1998;101: 2257-2267.
173. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-794.
174. - symporter. Nat Genet. 1997;17:122.
175. - symporter (NIS) function from analysis of a mutation that causes human congenital hypothyroidism. FEBS Lett. 1998;429:36-40.
176. +- symporters with inverted repeats. Curr Opin Struct Biol. 2009;19:425-432.
177. Krishnamurthy H, Piscitelli CL, Gouaux E. Unlocking the molecular secrets of sodium-coupled transporters. Nature. 2009;459:347-355.
178. +/betaine symporter BetP. Nature. 2009;458: 47-52.
179. +-independent and cooperative substrate/product antiport in CaiT. Nature. 2010;467:233-236.
180. Saito K, Yamamoto K, Yoshida S, et al. Goitrous hypothyroidism due to iodide-trapping defect. J Clin Endocrinol Metab. 1981;53:1267-1272.
181. Kosugi S, Inoue S, Matsuda A, Jhiang SM. Novel, missense and loss-of-function mutations in the sodium/iodide symporter gene causing iodide transport defect in three Japanese patients. J Clin Endocrinol Metab. 1998;83:3373-3376.
182. Singh SK, Piscitelli CL, Yamashita A, Gouaux E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science. 2008;322:1655-1661.
183. Singh SK, Yamashita A, Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature. 2007;448:952-956.
184. Forrest LR, Zhang YW, Jacobs MT, Gesmonde J, Xie L, Honig BH, Rudnick G. Mechanism for alternating access in neurotransmitter transporters. Proc Natl Acad SciUSA. 2008;105:10338-10343.
185. Tonacchera M, Agretti P, de Marco G, et al. Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. Clin Endocrinol (Oxf). 2003;59:500-506.
186. Wright EM. Active transport of iodide and other anions across the choroid plexus. J Physiol. 1974;240:535-566.
187. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology. 1997;138:3555-3558.
188. Perron B, Rodriguez AM, Leblanc G, Pourcher T. Cloning of the mouse sodium iodide symporter and its expression in the mammary gland and other tissues. J Endocrinol. 2001;170:185-196.
189. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab. 1998; 83:1746-1751.
190. - symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol. 1999;141:382-386.
191. - symporter in human thyroid tissues and salivary gland tissues. Endocrinology. 1998;139: 4416-4419.
192. Venturi S, VenturiM.Iodine in evolution of salivary glands and in oral health. Nutr Health. 2009;20:119-134.
193. Gupta A, Lakhoo K, Pritchard N, Herbert M. Epidermal growth factor in neonatal saliva. Eur J Pediatr Surg. 2008; 18:245-248.
194. Dagogo-Jack S. Dietary iodine affects epidermal growth factor levels in mouse thyroid and submaxillary glands. Endocr Res. 1994;20:247-257.
195. Geiszt M, Witta J, Baffi J, Lekstrom K, Leto TL. Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J. 2003;17: 1502-1504.
196. Thomas EL, Bates KP, Jefferson MM. Hypothiocyanite ion: detection of the antimicrobial agent in human saliva. J Dent Res. 1980;59:1466-1472.
197. - symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC Cancer. 2007;7:5.
198. - symporter mediates active iodide uptake in the intestine. Am J Physiol Cell Physiol. 2009;296:C654-C662.
199. +/ multivitamin transporter (hSMVT). J Biol Chem. 2011; 286:131-137.
200. Said HM. Cell and molecular aspects of human intestinal biotin absorption. J Nutr. 2009;139:158-162.
201. - symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004;10: 4294-4302.
202. Spitzweg C, Dutton CM, Castro MR, et al. Expression of the sodium iodide symporter in human kidney. Kidney Int. 2001;59:1013-1023.
203. - symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol. 2001;144:297-302.
204. Wapnir IL, van de Rijn M, Nowels K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880-1888.
205. Di Cosmo C, Fanelli G, Tonacchera M, et al. The sodiumiodide symporter expression in placental tissue at different gestational age: an immunohistochemical study. Clin Endocrinol (Oxf). 2006;65:544-548.
206. Mitchell AM, Manley SW, Morris JC, Powell KA, Bergert ER, Mortimer RH. Sodium iodide symporter (NIS) gene expression in human placenta. Placenta. 2001;22:256-258.
207. - symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab. 2000;85:4367-4372.
208. Wijkstrom-Frei C, El-Chemaly S, Ali-Rachedi R, et al. Lactoperoxidase and human airway host defense.AmJ Respir Cell Mol Biol. 2003;29:206-212.
209. Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med. 2007;175:174-183.
210. StoltzDA,MeyerholzDK,PezzuloAA,et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2:29ra31.
211. Fragoso MA, Fernandez V, Forteza R, Randell SH, Salathe M, Conner GE. Transcellular thiocyanate transport by human airway epithelia. J Physiol. 2004;561:183-194.
212. Suzuki K, Kawashima A, Yoshihara A, et al. Role of thyroglobulin on negative feedback autoregulation of thyroid follicular function and growth. J Endocrinol. 2011;209: 169-174.
213. Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012;135:355-370.
214. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels inFRTL-5cells. Endocrinology. 1997;138:2227-2232.
215. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMPdependent transcription. Mol Cell Biol. 1999;19:2051-2060.
216. - symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J Clin Endocrinol Metab. 1997;82:3331-3336.
217. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol. 2000;167:125-135.
218. Weiss SJ, Philp NJ, Ambesi-Impiombato FS, Grollman EF. Thyrotropin-stimulated iodide transport mediated by adenosine 3',5'-monophosphate and dependent on protein synthesis. Endocrinology. 1984;114:1099-1107.
219. Plummer HS. Results of administering iodine to patients having exophthalmic goiter. JAMA. 1923;80:1955.
220. Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem. 1948; 174:555-564.
221. Wolff J, Chaikoff IL, Goldberg RC, Meier JR. The temporary nature of the inhibitory action of excess iodide on organic iodide synthesis in the normal thyroid. Endocrinology. 1949;45:504-513.
222. Braverman LE, Ingbar SH. Changes in thyroidal function during adaptation to large doses of iodide. J Clin Invest. 1963;42:1216-1231.
223. Grollman EF, Smolar A, Ommaya A, Tombaccini D, Santisteban P. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology. 1986;118:2477-2482.
224. - symportermRNAs in dog thyroid. Mol Cell Endocrinol. 1997;131:195-203.
225. Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid. 1999;9:821-830.
226. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999;140:3404-3410.
227. Serrano-Nascimento C, Calil-Silveira J, Nunes MT. Posttranscriptional regulation of sodium-iodide symporter mRNA expression in the rat thyroid gland by acute iodide administration. Am J Physiol Cell Physiol. 2010;298: C893-C899.
228. Leoni SG, Kimura ET, Santisteban P, De la Vieja A. Regulation of thyroid oxidative state by thioredoxin reductase has a crucial role in thyroid responses to iodide excess. Mol Endocrinol. 2011;25:1924-1935.
229. Song Y, Driessens N, Costa M, et al. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab. 2007;92:3764-3773.
230. Corvilain B, Van Sande J, Dumont JE. Inhibition by iodide of iodide binding to proteins: the "Wolff-Chaikoff" effect is caused by inhibition of H2O2 generation. Biochem Biophys Res Commun. 1988;154:1287-1292.
231. Panneels V, Van Sande J, Van den Bergen H, et al. Inhibition of human thyroid adenylyl cyclase by 2-iodoaldehydes. Mol Cell Endocrinol. 1994;106:41-50.
232. Pereira A, Braekman JC, Dumont JE, Boeynaems JM. Identification of a major iodolipid from the horse thyroid gland as 2-iodohexadecanal. J Biol Chem. 1990;265: 17018-17025.
233. Panneels V, Macours P, Van den Bergen H, Braekman JC, Van Sande J, Boeynaems JM. Biosynthesis and metabolism of 2-iodohexadecanal in cultured dog thyroid cells. J Biol Chem. 1996;271:23006-23014.
234. Roepke TK, King EC, Reyna-Neyra A, et al. Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis. Nat Med. 2009;15:1186-1194.
235. Jespersen T, Grunnet M, Olesen SP. The KCNQ1 potassium channel: from gene to physiological function. Physiology. 2005;20:408-416.
236. Fröhlich H, Boini KM, Seebohm G, et al. Hypothyroidism of gene-targeted mice lacking Kcnq1. Pflugers Arch. 2011; 461:45-52.
237. - uptake. FASEB J. 2012;26:3252-3259.
238. Roepke TK, Anantharam A, Kirchhoff P, et al. The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion. J Biol Chem. 2006;281:23740-23747.
239. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920-980.
240. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
241. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
242. Groussin L, Fagin JA. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab. 2006;2: 180-181.
243. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 2004;209:1-6.
244. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol. 2009;21:296-303.
245. Mitsutake N, Miyagishi M, Mitsutake S, et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology. 2006;147:1014-1019.
246. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2010;121:4700-4711.
247. - targeting to the membrane. Endocr Relat Cancer. 2006;13:257-269.
248. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006;155:495-512.
249. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005;65:2465-2473.
250. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007; 13:1341-1349.
251. Liu D, Liu Z, Condouris S, Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab. 2007;92:2264-2271.
252. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92: 2840-2843.
253. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623-632.
254. Woodrum DT, Gauger PG. Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol. 2005; 89:114-121.
255. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 2007;3:260-269.
256. Middendorp M, Grünwald F. Update on recent developments in the therapy of differentiated thyroid cancer. Semin Nucl Med. 2010;40:145-152.
257. National Cancer Instititue. Surveillance epidemiology and end results. National Cancer Institute website. http://seer. cancer.gov/statfacts/html/thyro.html. Accessed August 12, 2013.
258. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7: 265-271.
259. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
260. Renier C, Yao C, Goris M, et al. Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol. 2009;16:962-968.
261. Renier C, Vogel H, Offor O, Yao C, Wapnir I. Breast cancer brain metastases express the sodium iodide symporter. J Neurooncol. 2010;96:331-336.
262. Liu B, Hervé J, Bioulac-Sage P, et al. Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. Gastroenterology. 2007;132:1495-1503.
263. Lacoste C, Hervé J, Bou Nader M, et al. Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res. 2012;72:5505-5515.
264. Serganova I, Ponomarev V, Blasberg R. Human reporter genes: potential use in clinical studies. Nucl Med Biol. 2007;34:791-807.
265. Penheiter AR, Russell SJ, Carlson SK. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther. 2012;12:33-47.
266. - symporter in human glioma cells by adenovirus- mediated gene delivery. Gene Ther. 2000;7:740-749.
267. Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59:2136-2141.
268. Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med. 2004;34:23-31.
269. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood. 2003;102:489-496.
270. Faivre J, Clerc J, Gérolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in Wistar rats. Cancer Res. 2004; 64:8045-8051.
271. Shen DH, Marsee DK, Schaap J, et al. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther. 2004;11:161-169.
272. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 2000; 60:3484-3492.
273. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661-668.
274. Niu G, Krager KJ,GrahamMM,HichwaRD,DomannFE. Noninvasive radiological imaging of pulmonary gene transfer and expression using the human sodium iodide symporter. Eur J Nucl Med Mol Imaging. 2005;32:534-540.
275. Miyagawa M, Anton M, Wagner B, et al. Non-invasive imaging of cardiac transgene expression with PET: comparison of the human sodium/iodide symporter gene and HSV1-tk as the reporter gene. Eur J Nucl Med Mol Imaging. 2005;32:1108-1114.
276. Miyagawa M, Beyer M, Wagner B, et al. Cardiac reporter gene imaging using the human sodium/iodide symporter gene. Cardiovasc Res. 2005;65:195-202.
277. Lee KH, Kim HK, Paik JY, et al. Accuracy of myocardial sodium/iodide symporter gene expression imaging with radioiodide: evaluation with a dual-gene adenovirus vector. J Nucl Med. 2005;46:652-657.
278. Rao VP, Miyagi N, Ricci D, et al. Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation. Transplantation. 2007;84:1662-1666.
279. Ricci D, Mennander AA, Pham LD, et al. Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts. Eur J Cardiothorac Surg. 2008;33:32-39.
280. Terrovitis J, Kwok KF, Lautamaki R, et al. Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. J Am Coll Cardiol. 2008;52:1652-1660.
281. Lautamäki R, Terrovitis J, Bonios M, et al. Perfusion defect size predicts engraftment but not early retention of intra-myocardially injected cardiosphere-derived cells after acute myocardial infarction. Basic Res Cardiol. 2011; 106:1379-1386.
282. Higuchi T, Anton M, Dumler K, et al. Combined reporter gene PET and iron oxide MRI for monitoring survival and localization of transplanted cells in the rat heart. J Nucl Med. 2009;50:1088-1094.
283. Seo JH, Jeon YH, Lee YJ, et al. Trafficking macrophage migration using reporter gene imaging with human sodium iodide symporter in animal models of inflammation. J Nucl Med. 2010;51:1637-1643.
284. Liepe K, Kotzerke J.Acomparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007; 28:623-630.
285. Shelley MD, Mason MD. Radium-223 for men with hormone- refractory prostate cancer and bone metastases. Lancet Oncol. 2007;8:564-565.
286. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403-418.
287. Illidge TM, Bayne MC. Antibody therapy of lymphoma. Expert Opin Pharmacother. 2001;2:953-961.
288. Hingorani M, White CL, Zaidi S, et al. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther. 2010;18:1599-1605.
289. - symporter gene. Endocrinology. 1997;138:4493-4496.
290. Chen RF, Li ZH, Pan QH, et al. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodiumiodide symporter. Pancreatology. 2007;7:505-513.
291. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther. 2006;17:661-668.
292. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther. 2006;13:60-66.
293. Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther. 2005;12:272-280.
294. Spitzweg C, BakerCH,Bergert ER, O'ConnorMK,Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promotertargeted sodium iodide symporter gene expression. Hum Gene Ther. 2007;18:916-924.
295. - symporter (NIS): recent advances. J Bioenerg Biomembr. 1998;30: 195-206.
296. Riedel C, Dohán O, De la Vieja A, Ginter CS, Carrasco N. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci. 2001;26:490-496.
297. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443-457.
298. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188-1200.
299. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf). 2002;57:559-574.
300. Baker CH, Morris JC. The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4: 167-174.
301. Chung JK, Kang JH. Translational research using the sodium/ iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging. 2004;31:799-802.
302. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 2003;63:7840-7844.
303. Willhauck MJ, Sharif Samani BR, et al. α-Fetoprotein promoter- targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther. 2008;15:214-223.
304. Hervé J, Cunha AS, Liu B, et al. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther. 2008;19:915-926.
305. Jin YN, Chung HK, Kang JH, et al. Radioiodine gene therapy of hepatocellular carcinoma targeted human α-fetoprotein. Cancer Biother Radiopharm. 2008;23:551-560.
306. Kim SH, Chung HK, Kang JH, et al. Tumor-targeted radionuclide imaging and therapy using human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Hum Gene Ther. 2008;19: 951-957.
307. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526-6530.
308. Spitzweg C, Dietz AB, O'ConnorMK,et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001;8:1524-1531.
309. Dwyer RM, Schatz SM, Bergert ER, et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther. 2005;12:835-841.
310. Ouellette MM, Wright WE, Shay JW. Targeting telomerase- expressing cancer cells. J Cell Mol Med. 2011;15: 1433-1442.
311. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov. 2006;5:577-584.
312. Riesco-Eizaguirre G, De la Vieja A, Rodríguez I, et al. Telomerase- driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach. J Clin Endocrinol Metab. 2011;96:E1435-E1443.
313. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology. 2006;44:1465-1477.
314. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98:2002-2007.
315. NakamuraT, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther. 2004;4:1685-1692.
316. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther. 2007;82:700-710.
317. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103:1641-1646.
318. Dingli D, Peng KW, Harvey ME, et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun. 2005;337:22-29.
319. Dingli D, Bergert ER, Bajzer Z, O'Connor MK, Russell SJ, Morris JC. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun. 2004;325:157-166.
320. Clinical trial (NCT00450814): vaccine therapy with or without cyclophosphamide in treating patients with recurrent or refractory multiple myeloma phase I trial of systemic administration of Edmonston strain of measles virus, genetically engineered to express NIS, with or without cyclophosphamide, in patients with recurrent or refractory multiple myeloma. http://clinicaltrials.gov/show/NCT00450814% 20MC038C%20P30CA015083%20MC038C%2006- 005263%20NCI-2009-01194%20NCT00450814. Accessed August 12, 2013.
321. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther. 2010;18:1155-1164.
322. Tatsuo H, Ono N, Tanaka K, Yanagi Y.SLAM(CDw150) is a cellular receptor for measles virus. Nature. 2000;406: 893-897.
323. Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75:295-305.
324. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther. 2009;11: 43-53.
325. Hummel HD, Kuntz G, Russell SJ, et al. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J Gen Virol. 2009; 90:693-701.
326. Calvo R, Obregon MJ, Ruiz de Ona C, Escobar del Rey F, Morreale de Escobar G. Congenital hypothyroidism, as studied in rats: crucial role of maternal thyroxine but not of 3,5,3'- triiodothyronine in the protection of the fetal brain. J Clin Invest. 1990;86:889-899.
327. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155-1159.
328. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5:429-441.
329. Magnon C, Opolon P, Ricard M, et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1α-mediated tumor apoptotic switch. J Clin Invest. 2007;117:1844-1855.
330. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000;275:1209-1215.
331. Friedlander M, Brooks PC, Shaffer RW, KincaidCM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science. 1995;270:1500-1502.
332. Magnon C, Galaup A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res. 2005;65:4353-4361.
333. Klutz K, Willhauck MJ, Dohmen C, et al. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Hum Gene Ther. 2011;22:1563-1574.
334. Klutz K, Russ V, Willhauck MJ, et al. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin Cancer Res. 2009;15:6079-6086.
335. Chisholm EJ, Vassaux G, Martin-Duque P, et al. Cancerspecific transgene expression mediated by systemic injection of nanoparticles. Cancer Res. 2009;69:2655-2662.
336. Fischer AJ, Lennemann NJ, Krishnamurthy S, et al. Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide. Am J Respir Cell Mol Biol. 2011; 45:874-881.
337. Dadachova E, Nguyen A, Lin EY, Gnatovskiy L, Lu P, Pollard JW. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol. 2005;32:695-700.
338. Willhauck MJ, Sharif Samani BR, et al. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab. 2007; 92:4451-4458.
339. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium- 188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol. 2002;29:13-18.
340. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J Nucl Med. 1995; 36:1902-1909.
341. 188Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. Hum Gene Ther. 2011;22:1403-1412.
342. Pedemonte N, Caci E, Sondo E, et al. Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels. J Immunol. 2007;178:5144-5153.